Literature DB >> 3521482

Reduction of cephamycin concentrations at the infection site in mice with experimental peritoneal infection caused by cephalosporinase-producing bacteria.

S Minami, H Araki, Y Watanabe, T Yasuda, A Takai, I Saikawa, S Mitsuhashi.   

Abstract

In an experimental model of peritoneal infection by cephalosporinase- (Ia and Ic) producing bacteria in mice, the reduction of cefoxitin, cefmetazole, and cefazolin concentrations in peritoneal fluid was observed in the mice infected with the Ia enzyme producer, whereas cefbuperazone concentrations were not reduced.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521482      PMCID: PMC176417          DOI: 10.1128/AAC.29.2.376

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Inactivation of cephamycins by various beta-lactamases from gram-negative bacteria.

Authors:  S Minami; N Matsubara; A Yotsuji; H Araki; Y Watanabe; T Yasuda; I Saikawa; S Mitsuhashi
Journal:  J Antibiot (Tokyo)       Date:  1984-05       Impact factor: 2.649

2.  In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic.

Authors:  M Tai; Y Fukuoka; A Yotsuji; K Kumano; M Takahata; H Mikami; T Yasuda; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Experimental infections for the evaluation of beta-lactamase resistance.

Authors:  L Xerri; P Orsolini; E Erani; R Broggio
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Characterization of beta-lactamase induction in Enterobacter cloacae.

Authors:  T D Gootz; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

5.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.